Skip to main content

Want a detailed portfolio tracker?

Performance analysis of SAB Biotherapeutics (SABS)

Annual Return

Over the past 3 years, SABS has had an average annual return of -27.62%, underperforming the benchmark SPY, which returned +22.77% annual.

Over the past 5 years, SABS has had an average annual return of -48.83%, underperforming the benchmark SPY, which returned +14% annual.

Since Feb 9, 2021, SABS has had an average annual return of -47.00%, underperforming the benchmark SPY, which returned +14.90% annual.

202620252024202320222021
-6.79%-1.60%-44.76%+16.52%-92.45%-23.05%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+17.66%-6.70%-6.68%-2.39%-3.53%-3.38%-6.79%
2025-42.25%-22.22%-20.24%+24.63%+13.77%-8.95%+6.94%+10.81%-3.41%+61.62%+21.56%-5.40%-1.60%
2024-12.70%-25.72%+1.82%-5.37%-38.53%+17.31%-10.49%+6.23%-8.28%+20.68%-10.28%+29.86%-44.76%
2023+15.15%-4.33%-32.34%+104.39%-0.90%-6.73%-2.44%-11.15%-12.41%+58.62%-2.74%-29.33%+16.52%
2022-25.61%-14.62%-24.21%-33.50%-21.60%-26.00%-25.54%-35.15%+0.14%+28.36%+19.95%-45.39%-92.45%
2021-0.69%-2.58%+1.32%-0.31%+0.43%-0.52%+0.60%+1.10%-21.53%+37.67%-28.28%-23.05%

Drawdown analysis of SAB Biotherapeutics (SABS)

The maximum drawdown for the SABS was -99.02%, occurring on Apr 7, 2025. This drawdown has not yet recovered.

The current SABS drawdown is -96.90%.

Since Feb 9, 2021 SABS has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 2 times
  • 20% or more: 3 times
  • 10% or more: 3 times
DepthStartTo BottomBottomTo RecoverEndTotal
-99.02%Dec 1, 2021839Apr 7, 2025OngoingOngoingOngoing
-30.28%Oct 18, 20215Oct 25, 202117Nov 17, 202122
-23.01%Nov 17, 20214Nov 23, 20215Dec 1, 20219
-6.07%Feb 18, 202125Mar 25, 2021143Oct 18, 2021168
-0.64%Feb 10, 20211Feb 11, 20211Feb 12, 20212
-0.64%Feb 16, 20211Feb 17, 20211Feb 18, 20212